Outcome | Description |
---|---|
Primary outcomes | Grade 2 or higher HFS (proportion) |
Secondary | All grades of HFS (proportion) Time to develop HFS (days) Patient-reported outcomes using HFS 14 questionnaire Adherence with topical application HFS related dose changes and delays in capecitabine Adverse events (NCI CTCAE version 5.0) |
Tertiary | COX-2 levels |